Deeptech startup Theranautilus raises $1.2 million in funding to transform dental care
-
Funding and Purpose: Bengaluru-based deeptech startup Theranautilus has secured $1.2 million in seed funding led by Pi Ventures, aiming to become the first global entity to commercialize nanorobotics-based medical devices, initially targeting dental hypersensitivity.
-
Innovative Technology: Founded in 2020, Theranautilus develops nanorobotic solutions that navigate dental tissues to deliver biocompatible materials for long-term repairs, offering a more effective alternative to traditional treatments.
-
Future Plans: The startup intends to establish an ISO-certified manufacturing facility to facilitate large-scale production of nanorobots and initiate human clinical trials by 2025, along with filing new international patents for their technologies.
- Broader Potential: Theranautilus’s innovative approach not only aims to revolutionize dental care but also holds potential applications in cancer therapy and various other medical fields, signaling a significant step toward minimally invasive treatments.
Theranautilus, a Bengaluru-based deeptech startup, has raised $1.2 million in seed funding led by Pi Ventures.
The round also saw participation from Golden Sparrow Ventures and angel investors, including Abhishek Goyal, CEO of Tracxn, and Lalit Keshre, CEO of Groww.
The funding aims to propel Theranautilus toward becoming the first global startup to commercialize nanorobotics-based medical devices, focusing initially on addressing dental hypersensitivity.
Innovating dental care with nanotechnology
Founded in 2020 by Professor Ambarish Ghosh, Dr. Debayan Dasgupta, and Dr. Peddi Shanmukh Srinivas, Theranautilus was incubated at the Indian Institute of Science (IISc).
The startup has developed cutting-edge nanorobotic solutions capable of navigating dental tissues and delivering biocompatible materials to repair damaged tissue. This approach offers a long-term solution compared to traditional treatments, such as specialized toothpastes.
The precision-manufactured nanorobots can be externally triggered to form bio-mimetic structures, providing lasting relief through a 10-minute procedure.
This innovation marks a significant leap in minimally invasive dental therapies, with potential applications extending into cancer therapy and other diseases.
“Nanorobots are currently made at a lab scale,” said Srinivas, co-founder and CEO of Theranautilus. “For clinical trials, we need to scale up production and develop devices to control these robots inside the human body.”
Establishing an ISO-certified manufacturing facility
Theranautilus plans to establish an ISO-certified manufacturing facility to support its go-to-market strategy. The facility will enable industrial-scale nanorobot production and pave the way for human trials, expected to begin in 2025.
The startup also aims to file new international patents to file new intellectual property rights.
According to Sohil Bhagat, principal at Pi Ventures, “Theranautilus’s revolutionary treatment for dental hypersensitivity could transform the multi-billion-dollar global industry and set new healthcare standards. Their adaptable nanotechnology platform promises to open avenues across multiple medical sectors.”
Here’s the information extracted from the provided text regarding the funds, investors, startup, founders, and fundraising series:
Startup
- Name: Theranautilus
- Location: Bengaluru, India
- Founded: 2020
- Focus: Nanorobotics-based medical devices, specifically for dental hypersensitivity
Founders
- Professor Ambarish Ghosh
- Dr. Debayan Dasgupta
- Dr. Peddi Shanmukh Srinivas
Funds Raised
- Amount: $1.2 million
- Funding Series: Seed funding
Investors
- Lead Investor: Pi Ventures
- Participating Investors:
- Golden Sparrow Ventures
- Angel Investors:
- Abhishek Goyal (CEO of Tracxn)
- Lalit Keshre (CEO of Groww)
Additional Information
- Incubation: Incubated at the Indian Institute of Science (IISc)
- Future Plans:
- Establish an ISO-certified manufacturing facility
- Scale up production for clinical trials expected to begin in 2025
- File new international patents for intellectual property rights
This summary encapsulates the key elements related to the startup Theranautilus and its initial fundraising round.